Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme Q10 for Oxaliplatin-Induced Neuropathy Prophylaxis
NCT06856447Phase 1Recruiting
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of coenzyme q10. Primary endpoint: Tumor necrosis factor-alpha. Started Jun 2024; status: recruiting.
02
Drugs
coenzyme q10
Beyond the preview
Go deeper on NCT06856447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06856447.